Pharmacyclics PT Raised to $103.00 at Morgan Stanley (PCYC)
Equities researchers at Morgan Stanley increased their price target on shares of Pharmacyclics (NASDAQ:PCYC) from $94.00 to $103.00 in a research report issued on Monday, AnalystRatingsNetwork reports. The firm currently has an “equal weight” rating on the stock. Morgan Stanley’s price target points to a potential downside of 13.60% from the company’s current price.
A number of other firms have also recently commented on PCYC. Analysts at Goldman Sachs Group Inc. raised their price target on shares of Pharmacyclics (NASDAQ:PCYC) from $102.00 to $111.00 in a research note to investors on Wednesday, September 18th. They now have a “buy” rating on the stock. Separately, analysts at Lazard Capital Markets upgraded shares of Pharmacyclics (NASDAQ:PCYC) from a “neutral” rating to a “buy” rating in a research note to investors on Wednesday, September 4th. They now have a $141.00 price target on the stock. Finally, analysts at Roth Capital raised their price target on shares of Pharmacyclics (NASDAQ:PCYC) from $120.00 to $130.00 in a research note to investors on Friday, August 30th. They now have a “buy” rating on the stock.
Five research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Pharmacyclics has an average rating of “Buy” and a consensus price target of $118.92.
Pharmacyclics (NASDAQ:PCYC) traded down 1.28% on Monday, hitting $119.21. The stock had a trading volume of 385,210 shares. Pharmacyclics has a one year low of $44.91 and a one year high of $123.94. The stock has a 50-day moving average of $115.2 and a 200-day moving average of $93.86. The company has a market cap of $8.720 billion and a price-to-earnings ratio of 117.47.
Pharmacyclics (NASDAQ:PCYC) last announced its earnings results on Wednesday, July 31st. The company reported $0.26 EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.07) by $0.33. The company had revenue of $54.70 million for the quarter, compared to the consensus estimate of $52.00 million. On average, analysts predict that Pharmacyclics will post $-0.16 earnings per share for the current fiscal year.
Pharmacyclics, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.